# Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct07745790/  
OnCo record `nct07745790` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sintilimab and tegafur, gimeracil and oteracil (S-1) in pancreatic cancer, run by Ruijin Hospital, not yet recruiting.

## Summary

Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT07745790 by Ruijin Hospital, with a registry enrolment figure of 20 participants, started 2026-07-13 and due to reach its primary completion in 2029-07-31. Interventions recorded: Multimodal Thermal Therapy (MTT) System; KRAS G12V mRNA Vaccine; Sintilimab; S-1. Conditions listed: Pancreatic Ductal Adenocarcinoma; Liver Neoplasms; Lung Neoplasms. Primary outcome: Incidence and Severity of Adverse Events (CTCAE v6.0); Frequency of Dose Modifications and Treatment Discontinuations. Pancreatic eligibility wording from the registry: "* Patients with advanced pancreatic cancer or postoperative recurrent pancreatic cancer confirmed by histopathological or cytological examination". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07745790
- Phase: 2
- Setting: A Study of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab for Safety and Efficacy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Disease Progression After or Are Intolerant to Standard First-Line Therapy
- Sponsor: Ruijin Hospital
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT07745790: https://clinicaltrials.gov/study/NCT07745790

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- drugs: [Sintilimab](https://onco.cc/drugs/sintilimab/), [Tegafur, gimeracil and oteracil (S-1)](https://onco.cc/drugs/tegafur-gimeracil-oteracil/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07745790.json